Are you interested in learning more about the existing patient referral pathways for advanced therapies in the UK and how these can be improved?
Watch the Webinar
Please provide your details to gain access.
The Cell and Gene Therapy Catapult takes your data very seriously. By using this form you are consenting to the processing of your personal data as per ourprivacy policy.
As the spread and scale of advanced therapies increases, efficient and effective processes which ensure patients are referred into specialist centres are essential to avoid any impact on treatment efficacy. It is also a priority to enable patient access to clinical trials whilst maximising opportunities for clinical sites to recruit.
This webinar will provide an overview of two projects that assessed patient referral pathways for different advanced therapies and the resulting best practice recommendations.
- Identification and analysis of CAR-T patient referral pathways in the UK, with recommendations to make improvements; proposed reforms will help to ensure that referral pathways remain appropriate for the next five years of CAR-T therapy and beyond in delivering equitable access to CAR-T for eligible patients.
- The advancement of gene therapy clinical trials in Duchenne muscular dystrophy (DMD) and the recent accelerated approval of a gene therapy product for use in a limited cohort of DMD patients in the United States. This indicates an immediate need to discuss gene therapy and the referral processes for DMD patients in the UK and a proposed set of recommendations for improved standardised future practice will be dissected.
Speakers
Chair: Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
Fiona Thistlethwaite, iMATCH Director and Medical Oncology Consultant within the ECMT (Experimental Cancer Medicine Team) at The Christie NHS Foundation Trust
Michela Guglieri, Senior Clinical Lecturer and Consultant Neurologist at Newcastle University and Newcastle Hospitals NHS Foundation Trust